TD Private Client Wealth LLC Boosts Stock Holdings in GSK plc (NYSE:GSK)

TD Private Client Wealth LLC raised its position in GSK plc (NYSE:GSK) by 36.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,422 shares of the pharmaceutical company’s stock after purchasing an additional 3,346 shares during the period. TD Private Client Wealth LLC’s holdings in GSK were worth $508,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Eastern Bank acquired a new position in GSK in the third quarter valued at $26,000. Sunbelt Securities Inc. lifted its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners boosted its holdings in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in GSK during the 2nd quarter worth approximately $37,000. Finally, Fortitude Family Office LLC acquired a new position in GSK during the third quarter worth $42,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Plc Gsk bought 2,791,930 shares of GSK stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GSK. Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of GSK opened at $33.95 on Friday. The business’s 50-day moving average is $36.18 and its 200-day moving average is $39.25. GSK plc has a fifty-two week low of $32.83 and a fifty-two week high of $45.92. The company has a market capitalization of $70.36 billion, a price-to-earnings ratio of 22.05, a P/E/G ratio of 1.54 and a beta of 0.64. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be issued a $0.3928 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.63%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s payout ratio is 99.35%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.